Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 367
Gene Symbol: AR
AR
0.600 Biomarker disease BEFREE Androgen has dual effects on BC via different metabolic pathways, and the role of the androgen receptor (AR) in BC also depends on cell subtype and downstream target genes. 31693255 2020
Entrez Id: 367
Gene Symbol: AR
AR
0.600 Biomarker disease BEFREE The standardization of AR detection methods could render AR an easily detectable marker in primary BC and metastatic samples. 31002873 2020
Entrez Id: 367
Gene Symbol: AR
AR
0.600 Biomarker disease BEFREE Studies targeting the androgen receptor (AR) signaling pathway in aromatase inhibitor (AI)-resistant breast cancer are limited.Bicalutamide, one of the commonly used AR inhibitors in prostate cancer, in combination with AI, did not show synergistic activity in patients with estrogen receptor-positive and AI-resistant disease in this phase II, single-arm study.The clinical benefit rate and objective response rate at 6 months were 16.7% and 0%, respectively, and the study was terminated after the first stage. 31434793 2020
Entrez Id: 367
Gene Symbol: AR
AR
0.600 Biomarker disease BEFREE Androgen treatment inhibits ER signaling in ER+/AR+ breast cancer cell lines, and AR expression is associated with improved survival for this subtype in epidemiologic studies. 30795773 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.600 Biomarker disease BEFREE Divergent roles for androgen receptor (AR) in breast cancer have been reported. 31289138 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.600 AlteredExpression disease BEFREE Treatment of MDA-MB-453 with CREBBP/EP300 bromodomain inhibitors downregulates the expression of an AR-dependent signature distinctive of breast cancer tumors that express AR and causes a decrease in H3K27ac levels at AR-binding sites. 30606771 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.600 Biomarker disease BEFREE Phase Ib patients (ER+ or TNBC) with AR+ breast cancer received 160 mg enzalutamide in combination with taselisib to determine dose-limiting toxicities and the maximum tolerated dose (MTD). 31822498 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.600 Biomarker disease BEFREE Unlike canonical AR signaling which is inhibited by enzalutamide, non-canonical AR activity is not effectively antagonized by enzalutamide, and this has important implications in the design of future AR-targeted clinical trials in endocrine-resistant breast cancer. 30557851 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.600 Biomarker disease BEFREE The positivities of estrogen receptor, progesterone receptor, and androgen receptor were lower (p < 0.001, p = 0.03, and p < 0.001, respectively), and the triple-negative (TN) BCs rates were higher (p < 0.01) in the AYA group. 30539373 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.600 Biomarker disease BEFREE In this review, we aim to address the importance of the AR in BCa diagnosis and prognosis, current AR-targeting approaches in BCa, and the potential for AR-downstream molecules to serve as therapeutic targets. 30821186 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.600 AlteredExpression disease BEFREE In this study, the diagnostic utility of a panel of SOX10, GATA3, and androgen receptor (AR) in MBC negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 was evaluated and compared with the expression of these markers in the matched primary breast cancer. 30468800 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.600 Biomarker disease BEFREE A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer. 31367790 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.600 Biomarker disease BEFREE In conclusion, next to AR expression, incorporation of additional tumor characteristics will potentially make AR targeting a more valuable therapeutic strategy in breast cancer. 31077689 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.600 AlteredExpression disease BEFREE Furthermore, inhibition of 17β-HSD7 increases the expression of AR gene which is considered as a marker for better prognosis in ER + breast cancer, while maintaining ERα level. 31207361 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.600 Biomarker disease BEFREE We characterized and tested a novel therapy to an AR-governed target in breast cancer.<b>Experimental Design:</b> We evaluated the expression of prototypical AR gene products human kallikrein 2 (hK2) and PSA in breast cancer models. 30254080 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.600 Biomarker disease BEFREE The androgen receptor (AR) is present in most breast cancers (BC), but its exploitation as a therapeutic target has been limited.This study explored the activity of dehydroepiandrosterone (DHEA), a precursor being transformed into androgens within BC cells, in combination with an aromatase inhibitor (to block DHEA conversion into estrogens), in a two-stage phase II study in patients with AR-positive/estrogen receptor-positive/human epidermal growth receptor 2-negative metastatic BC.Although well tolerated, only 1 of 12 patients obtained a prolonged clinical benefit, and the study was closed after its first stage for poor activity. 30591548 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.600 AlteredExpression disease BEFREE Using immunohistochemistry, ANK3 protein expression was evaluated in large (n = 982) cohort of early-stage BC with long-term follow-up and compared with clinicopathological characteristics and its prognostic value in the whole cohort and the subgroups stratified by AR protein expression. 30941650 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.600 Biomarker disease BEFREE Androgen receptor (AR) has been extensively studied, but its role in relation to breast cancer patient prognosis remains to be clarified. 31110518 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.600 AlteredExpression disease BEFREE We provide evidence that AR mRNA predicts response to chemotherapy in breast cancer patients. 31728025 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.600 Biomarker disease BEFREE Lastly, as Androgen Receptor and Estrogen Receptor PROTAC degraders are being pursued as treatment for prostate cancer and breast cancer, respectively, a rationale is provided for the translational utility for the degradation of these two NRs. 31125586 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.600 Biomarker disease BEFREE Immunohistochemistry was used to evaluate the presence of CPA4, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki67, epidermal growth factor receptor, cytokeratin 5/6, aldehyde dehydrogenase 1, cluster of differentiation (CD)44, CD24, claudins, E‑cadherin, vimentin and androgen receptor in 221 cases of breast cancer, including 68 TNBC cases. 30628666 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.600 AlteredExpression disease BEFREE Our analyses suggest that the heterogeneity of TNBC is at least partially associated with the presence or absence of AR expression, suggesting that QNBC should be considered as a clinically relevant BC subtype. 30594038 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.600 AlteredExpression disease BEFREE Our data suggest that sPSA may reflect tumor biological properties including AR activity in post-menopausal breast cancer. 31664946 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.600 Biomarker disease BEFREE We have previously reported that deubiquitinase USP14 stabilizes AR proteins by deubiquitination and USP14 inhibition results in inhibition of cell growth and tumor progression in AR-positive prostate cancer and breast cancer. 31126320 2019
Entrez Id: 367
Gene Symbol: AR
AR
0.600 Biomarker disease BEFREE The purpose of this review is to present a state of the art scenario with consideration to the most recent discoveries about miRNAs involved in the AR associated pathogenesis of BC, in order to provide new insights into the role of miRNAs as key drivers in the modulation of AR, and possible actors in the development and progression of BC. 30941159 2019